EFFECT OF FENOFIBRATE ADJUVANT THERAPY ON ENDOTHELIAL DYSFUNCTION AND CARDIOVASCULAR RISK IN EGYPTIAN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Objective: Endothelial dysfunction is afflicted to the maturation of arteriosclerosis and type 2 diabetes mellitus (T2DM) vascular complications. This study designed to evaluate the impact of fenofibrate adjuvant therapy on endothelial dysfunction and cardiovascular risk in patients with T2DM.
Methods: Seventy-five subjects were recruited from the Internal Medicine Department of Tanta University Hospital. The participants were classified into three groups: Group 1 (control group), 25 healthy subjects; Group 2, 25 T2DM patients received glimepiride/metformin (2:500 mg/day); and Group 3, 25 T2DM patients received glimepiride/metformin (2:500 mg/day)+fenofibrate (300 mg/day). Patients were assessed before and 3 months after intervention for the determination of body mass index (BMI), blood pressure, glycemic picture (hemoglobin A1C % and homeostatic model assessment of insulin resistant), lipid panel, Castelli’s risk index (CRI-I and CRI-II), albumin-to-creatinine ratio (ACR), and endothelial dysfunction biomarkers (asymmetric dimethylarginine [ADMA] and Syndecan-1 (SDC-1)]. Data were statistically analyzed by one-way analysis of variance; p<0.05 was considered statistically significant.
Results: The addition of fenofibrate to oral hypoglycemic drugs (Group 3) provoked a significant decrease in all measured parameters when compared with Group 2. As compared to the control group, Group 3 showed no significant difference in most measured parameters after 3 months of therapy. For T2DM patients of Group 3, both ADMA and SDC-1 showed a significant positive correlation with all measured parameters except for high-density lipoprotein cholesterol which exhibited significant negative correlation after 3 months of therapy (p<0.05).
Conclusion: The addition of fenofibrate adjuvant therapy to oral hypoglycemic drugs improved the vascular endothelial dysfunction, CRI-I, CRI-II, glycemic picture, lipid panel, ACR, and blood pressure and reduced the BMI in patients with T2DM.
2. Suganami T, Tanaka M, Ogawa Y. Adipose tissue inflammation and ectopic lipid accumulation. Endocr J 2012;59:849-57.
3. Kumar A, Singh V. Atherogenic dyslipidemia and diabetes mellitus: What’s new in the management arena? Vasc Health Risk Manag 2010;6:665-9.
4. Bhardwaj S, Bhattacharjee J, Bhatnagar MK, Tyagi S. Atherogenic index of plasma, castelli risk index and atherogenic coefficient- new parameters in assessing cardiovascular risk. Int J Pharm Bio Sci 2013;3:359-64.
5. Ebara T, Conde K, Kako Y, Liu Y, Xu Y, Ramakrishnan R, et al. Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice. J Clin Invest 2000;105:1807-18.
6. Hayashida K, Parks WC, Park PW. Syndecan-1 shedding facilitates the resolution of neutrophilic inflammation by removing sequestered CXC chemokines. Blood 2009;114:3033-43.
7. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM Jr., et al. Circulating adhesion molecules VCAM-1, ICAM-1 and SE-selectin in carotid atherosclerosis and incident coronary heart disease cases: The Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997;96:4219-25.
8. Cooke JP, Dzau VJ. Nitric oxide synthase: Role in the genesis of vascular disease. Annu Rev Med 1997;48:489-509.
9. Leone A, Moncada S, Vallance P, Calver A, Collier J. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;8793:572-5.
10. Zambon A, Cusi K. The role of fenofibrate in clinical practice. Diab Vasc Dis Res 2007;4 Suppl 3:S15-20.
11. Kalsi A, Singh S, Taneja N, Kukal S, Mani S. Current treatments for Type 2 diabetes, their side effects and possible complementary treatments. Int J Pharm Pharm Sci 2015;3:13-8.
12. Walker AE, Kaplon RE, Lucking SM, Russell-Nowlan MJ, Eckel RH, Seals DR. Fenofibrate improves vascular endothelial function by reducing oxidative stress while increasing endothelial nitric oxide synthase in healthy normolipidemic older adults. Hypertension 2012;60:1517-23.
13. Pruski M, Krysiak R, Okopien B. Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in Type 2 diabetic patients with mixed dyslipidemia. Diabetes Care 2009;32:1421-4.
14. Chen XR, Besson VC, Palmier B, Garcia Y, Plotkine M, Marchand-Leroux C. Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury. J Neurotrauma 2007;24:1119-31.
15. Kaplan LA, editor. Glucose. In: Clinical Chemistry. St Louis, Toronto: The CV Mosby Co.; 1984. p. 1032-6.
16. Bissé E, Abraham EC. New less temperature-sensitive microchromatographic method for the separation and quantitation of glycosylated hemoglobins using a non-cyanide buffer system. J Chromatogr 1985;344:81-91.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
18. Watson D. A simple method for the determination of serum cholesterol. Clin Chim Acta 1960;5:637-43.
19. Fossati P, Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 1982;28:2077-80.
20. Warnick GR, Wood PD. National Cholesterol Education Program recommendations for measurement of high-density lipoprotein cholesterol: Executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. Clin Chem 1995;41:1427-33.
21. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
22. Oguejiofor OC, Onwukwe CH, Odenigbo CU. Dyslipidemia in Nigeria: Prevalence and pattern. Ann Afr Med 2012;11:197-202.
23. Ogbera AO, Fasanmade OA, Chinenye S, Akinlade A. Characterization of lipid parameters in diabetes mellitus a Nigerian report. Int Arch Med 2009;2:19.
24. Keating GM, Ormrod D. Micronised fenofibrate: An updated review of its clinical efficacy in the management of dyslipidaemia. Drugs 2002;62:1909-44.
25. Kleemann R, Verschuren L, de Rooij BJ, Lindeman J, de Maat MM, Szalai AJ, et al. Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood 2004;103:4188-94.
26. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998;393:790-3.
27. Koanantakul B, Jeamanukulkit N, Piamsomboon C, Chawantanpipat C, Khanacharoen I. Efficacy and safety of 12-week treatment with fenofibrate 300 mg in Thai dyslipidemic patients. J Med Assoc Thai 2004;87:1281-5.
28. Filippatos TD, Kiortsis DN, Liberopoulos EN, Georgoula M, Mikhailidis DP, Elisaf MS. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: The FenOrli study. Curr Med Res Opin 2005;21:1997-2006.
29. Koh KK, Quon MJ, Han SH, Chung WJ, Ahn JY, Kim JA, et al. Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients. Diabetes Care 2006;29:195-201.
30. American Diabetes Association. Classification and diagnosis of diabetes. Diabetes Care 2017;40 Suppl 1:11-24.
31. Haghighatpanah M, Thunga G, Khare S, Mallayasamy S. Correlation of glycosylated hemoglobin levels with fasting and postprandial glucose in South Indian Type 2 diabetic patients. Int J Pharm Pharm Sci 2016;8:285-8.
32. Damci T, Tatliagac S, Osar Z, Ilkova H. Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in Type 2 diabetic patients with hypertriglyceridemia. Eur J Intern Med 2003;14:357-60.
33. Giancaterini A, De Gaetano A, Mingrone G, Gniuli D, Liverani E, Capristo E, et al. Acetyl-L-carnitine infusion increases glucose disposal in Type 2 diabetic patients. Metabolism 2000;49:704-8.
34. DeFronzo RA, Del Prato S. Insulin resistance and diabetes mellitus. J Diabetes Complications 1996;10:243-5.
35. Miyazaki T, Shimada K, Miyauchi K, Kume A, Tanimoto K, Kiyanagi T, et al. Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and in-stent intimal hyperplasia in patients after elective coronary stenting. Lipids Health Dis 2010;9:122.
36. Nair D, Carrigan TP, Curtin RJ, Popovic ZB, Kuzmiak S, Schoenhagen P, et al. Association of total cholesterol/high-density lipoprotein cholesterol ratio with proximal coronary atherosclerosis detected by multislice computed tomography. Prev Cardiol 2009;12:19-26.
37. Olamoyegun MA, Oluyombo R, Asaolu SO. Evaluation of dyslipidemia, lipid ratios, and atherogenic index as cardiovascular risk factors among semi-urban dwellers in Nigeria. Ann Afr Med 2016;15:194-9.
38. Wang JB, Zhang YJ, Zhang Y, Guan J, Chen LY, Fu CH, et al. Negative correlation between serum syndecan-1 and apolipoprotein A1 in patients with Type 2 diabetes mellitus. Acta Diabetol 2013;50:111-5.
39. Bangstad HJ, Østerby R, Rudberg S, Hartmann A, Brabrand K, Hanssen KF. Kidney function and glomerulopathy over 8 years in young patients with Type I (insulin-dependent) diabetes mellitus and microalbuminuria. Diabetologia 2002;45:253-61.
40. Ha TS, Duraisamy S, Faulkner JL, Kasinath BS. Regulation of glomerular endothelial cell proteoglycans by glucose. J Korean Med Sci 2004;19:245-52.
41. Svennevig K, Kolset SO, Bangstad HJ. Increased syndecan-1 in serum is related to early nephropathy in Type 1 diabetes mellitus patients. Diabetologia 2006;49:2214-6.
42. Fard A, Tuck CH, Donis JA, Sciacca R, Di Tullio MR, Wu HD, et al. Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with Type 2 diabetes. Arterioscler Thromb Vasc Biol 2000;20:2039-44.
43. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 2003;24:1912-9.
44. Okopie? B, Cwalina ?, Haberka M, Kowalski J, Zieli?ski M, Szwed Z, et al. Pleiotropic effects of micronized fenofibrate in patients with combined hyperlipidemia. Pol Merkur Lekarski 2002;13:465-9.
45. Yang TL, Chen MF, Luo BL, Yu J, Jiang JL, Li YJ. Effect of fenofibrate on LDL-induced endothelial dysfunction in rats. Naunyn Schmiedebergs Arch Pharmacol 2004;370:79-83.
46. Davis TM, Ting R, Best JD, Donoghoe MW, Drury PL, Sullivan DR, et al. Effects of fenofibrate on renal function in patients with Type 2 diabetes mellitus: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011;54:280-90.
47. Jun M, Zhu B, Tonelli M, Jardine MJ, Patel A, Neal B, et al. Effects of fibrates in kidney disease: A systematic review and meta-analysis. J Am Coll Cardiol 2012;60:2061-71.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.